Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Schrodinger today. The company’s shares closed yesterday at $21.21.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hewitt covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Omnicell, and Repligen. According to TipRanks, Hewitt has an average return of -1.6% and a 44.33% success rate on recommended stocks.
Schrodinger has an analyst consensus of Moderate Buy, with a price target consensus of $25.06.
SDGR market cap is currently $1.56B and has a P/E ratio of -8.54.
Read More on SDGR:
Disclaimer & DisclosureReport an Issue
- Hold Rating on Schrodinger Amid Uncertainty in Software Growth and Promising Drug Pipeline
- Schrodinger initiated with a Neutral at Goldman Sachs
- Schrodinger Announces CFO Geoffrey Porges’ Departure
- Private Markets: Anthropic raises $13B Series F at $183B post-money valuation
- Schrodinger downgraded to Neutral from Buy at Citi
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)